Partnering with Clinicians and Researchers to Advance Precision Therapies
Empowering medical professionals with the science, data, and tools needed to deliver transformative gene and RNA therapies to patients in need
Clinical Information for Medical Professionals
A clinician-facing page for Hurler syndrome (MPS I-H) awareness, diagnostic referral support, and practical shared-care guidance. This section is designed to help clinicians recognise key red flags, refer early, and access structured educational resources.
Quick actions
Clinical summary at a glance
HCP quick referenceRecognise early and refer urgently
When Hurler syndrome is suspected, prompt contact with a specialist inherited metabolic disease service is important, especially in young children.
Diagnosis is multi-step
Diagnosis is based on clinical assessment plus biochemical and molecular confirmation, with newborn screening acting as an early flag in some settings.
Current treatment pillars
Clinical care is built around HSCT, ERT with laronidase, and long-term multidisciplinary supportive care.
HSCT remains central in severe MPS I-H
Early transplant assessment is important for children with confirmed severe disease who are suitable candidates.
Peri-anaesthetic risk needs planning
Airway narrowing, cervical spine pathology, and cardio-respiratory involvement can significantly increase sedation and anaesthetic risk.
Shared-care matters long term
Patients often require coordinated follow-up across cardiology, respiratory, orthopaedics, ENT, ophthalmology, audiology, neurology, and developmental services.
Suggested diagnostic and referral flow
Structured approachClinical suspicion
Consider Hurler syndrome in infants or young children with multisystem features such as recurrent infections, hernias, coarse facial features, developmental concerns, skeletal or joint abnormalities, and organ involvement.
Urgent metabolic referral
Do not wait for every result before discussing with a specialist metabolic team. Early referral supports faster assessment and time-sensitive treatment planning.
Initial diagnostic work-up
Coordinate local and specialist testing pathways. Newborn screening may identify low IDUA activity first in some countries, but screening is not diagnostic on its own.
Biochemical and molecular confirmation
Confirm diagnosis using enzyme and genetic testing in line with local practice, and interpret findings alongside clinical features.
Phenotype stratification and HSCT assessment
Differentiate severe MPS I-H from attenuated forms and assess treatment pathway suitability with a recognised metabolic and transplant centre.
Shared-care plan and surveillance
Establish a multidisciplinary follow-up plan with clear responsibilities between the specialist centre and local teams.
Rapid referral checklist
Use in clinic / ward- Document key clinical features and symptom timeline
- Record family history and any previous genetics or metabolic work-up
- Capture growth, neurodevelopment, and functional concerns
- Note prior surgeries, airway concerns, or anaesthetic issues
- Young child with multisystem findings suggestive of MPS I-H
- Positive newborn screen or low IDUA on screening pathway
- Progressive respiratory, cardiac, or neurodevelopmental concerns
- Need for anaesthesia or surgery before diagnosis is clarified
- Send referral summary to metabolic centre and relevant local specialists
- Identify a named local lead clinician
- Document emergency and perioperative risk considerations
- Arrange early MDT discussion where possible
Current care framework for clinicians
Established care pillarsHSCT
In severe MPS I-H, HSCT is a core disease-modifying treatment and is generally prioritised for suitable children, with timing and candidacy assessed by specialist teams.
ERT with laronidase
ERT supports somatic disease management, may be used around transplant pathways, and remains important in patients who are not transplanted or who have residual disease burden.
Multidisciplinary supportive care
Supportive care is central, lifelong care. It is not an add-on. It often drives day to day quality of life and long-term function even after HSCT or during ERT.
Anaesthetic considerations
Hurler syndrome can carry higher risk during sedation, anaesthesia, and recovery. Airway narrowing, cervical spine pathology, and cardio-respiratory involvement should be identified early and planned for with senior anaesthetic support.
- Flag high-risk airways in advance
- Review cervical spine concerns before procedures
- Coordinate with anaesthesia and ICU teams where needed
- Share emergency information across teams
MDT domains to review regularly
Structured follow-up should be proactive. A practical MDT framework usually spans organ surveillance, development, function, and perioperative readiness.
- Cardiology: ECG and echo follow-up
- Respiratory / ENT: airway, sleep, infections, hearing
- Orthopaedics: spine, hips, joints, mobility
- Neurology / neurosurgery: CNS and cervical spine concerns
- Ophthalmology and audiology reviews
- Development, rehabilitation, psychosocial support
Clinical education and reference resources
HurlerSyndrome.org HCP resourcesRequest a Medical Professional Information Pack
Professional enquiry formSuggested contents for the HCP pack
A polished PDF or slide-style pack for clinicians, hospitals, and MDT teams. You can tailor the pack by audience (general paediatrics, metabolic, ENT, orthopaedics, anaesthesia, ICU, etc.).
- Hurler syndrome overview and key recognition features
- Referral pathway summary for suspected MPS I-H
- HSCT and ERT care context (high-level clinician summary)
- Multisystem follow-up domains and perioperative alerts
- Links to detailed HCP education pages on HurlerSyndrome.org
- Dawn Therapeutics preclinical programme and contact details
Clinical Resources
We provide healthcare professionals with:
Disease Education Materials
Updated information on the epidemiology, pathophysiology, and genetic basis of targeted diseases
Treatment Mechanism Overviews
Easy-to-understand summaries of how our therapies work at the molecular level.
Diagnostic Guidelines
Tools to aid early identification and referral
Continuing Medical Education (CME)
Access to scientific webinars and accredited learning sessions.
Medical Affairs Team
Our Medical Affairs team provides:
Rapid response to clinical queries.
Access to scientific data and safety information.
Collaboration on publications and congress presentations.
Collaboration Opportunities
Investigator-Initiated Trials (IITs)
Submit proposals for Dawn-supported research.
Biomarker Development Projects
Work with our R&D team on validation studies.
Registry & Natural History Studies
Contribute data to accelerate research in rare diseases.
